Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 141

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood blood.2024024582.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

MRD accelerating myeloma drug development

Luciano J. Costa

Blood (2024) 144 (4): 345–347.

https://doi.org/10.1182/blood.2024025421

Published: 2024

Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard

Blood (2022) 140 (Supplement 1): 1360–1362.

https://doi.org/10.1182/blood-2022-160038

Published: 2022

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Blood (2022) 140 (Supplement 1): 1146–1149.

https://doi.org/10.1182/blood-2022-162313

Published: 2022

Journal Articles

Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant

Nicole Watts, Courtney Hebert, Clare Ubersax, Deanna Clark, Gayathri Ravi, Susan Bal, Purnima Singh, Kelly N. Godby, Donna Salzman, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2022) 140 (Supplement 1): 5248–5249.

https://doi.org/10.1182/blood-2022-163649

Published: 2022

Journal Articles

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle, Hang Quach, Sandy W. Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesus Berdeja, Sébastien Anguille, Jeffrey V. Matous, Cyrille Touzeau, Anne-Sophie Michallet, Marla Husnik, Deeksha Vishwamitra, Zhuolu Niu, Julie Larsen, Lingling Chen, Jenna D. Goldberg, Rakesh Popat, Andrew Spencer

Blood (2022) 140 (Supplement 1): 394–396.

https://doi.org/10.1182/blood-2022-159711

Published: 2022

Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Blood (2022) 140 (Supplement 1): 4393–4395.

https://doi.org/10.1182/blood-2022-160071

Published: 2022

Journal Articles

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 384–387.

https://doi.org/10.1182/blood-2022-159707

Published: 2022

Journal Articles

Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy

Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Gregory Calip, Mustafa S Ascha, Xiaoliang Wang, Samuel Rubinstein, Sascha A. Tuchman, Luciano J. Costa, Benjamin Haaland, Smith Giri, Hira S Mian, Rafael Fonseca, Douglas W. Sborov

Blood (2022) 140 (Supplement 1): 5223–5224.

https://doi.org/10.1182/blood-2022-165541

Published: 2022

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 4447–4449.

https://doi.org/10.1182/blood-2022-162555

Published: 2022

Journal Articles

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Smith Giri, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy Martin Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Anita D'Souza, Aric C. Hall, Pamela Hardwick, Jim Omel, Robert Frank Cornell, Natalie Callander, Parameswaran Hari, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 4431–4433.

https://doi.org/10.1182/blood-2022-160381

Published: 2022

Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Blood (2022) 140 (Supplement 1): 4415–4417.

https://doi.org/10.1182/blood-2022-157547

Published: 2022

Journal Articles

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, M. Hakan Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Jr., Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison J. Kaeding, Michael R. Burgess, Kristen Hege, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 883–885.

https://doi.org/10.1182/blood-2022-162395

Published: 2022

Journal Articles

Survival of Patients with Extranodal NK-Cell Lymphoma in the United States

Ana C. Xavier, Nader Kim El-Mallawany, Matt J. Ehrhardt, Luciano J. Costa, Mitchell S. Cairo

Blood (2022) 140 (Supplement 1): 6563–6564.

https://doi.org/10.1182/blood-2022-160023

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Blood (2022) 140 (Supplement 1): 7278–7281.

https://doi.org/10.1182/blood-2022-162339

Published: 2022

Journal Articles

Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens

Luciano J. Costa, Kelly N. Godby, Gayathri Ravi, Smith Giri, Susan Bal

Blood (2022) 140 (Supplement 1): 10084–10085.

https://doi.org/10.1182/blood-2022-165882

Published: 2022

Journal Articles

Evaluating Concordance between International Myeloma Working Group (IMWG) and Simplified Frailty Index (SFI) Among Older Adults with Multiple Myeloma (MM)

Andrew Gahagan, Sunil Rangarajan, Clare Ubersax, Abigail Tucker, Christian Harmon, Monica Sai Pasala, Susan Bal, Kelly N. Godby, Gayathri Ravi, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2022) 140 (Supplement 1): 10079–10080.

https://doi.org/10.1182/blood-2022-165432

Published: 2022

Journal Articles

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Timothy Martin Schmidt, Rebecca Silbermann, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N. Godby, Sonia Gowda, Eva Medvedova, Natalie Callander, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10077–10078.

https://doi.org/10.1182/blood-2022-164930

Published: 2022

Journal Articles

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Salyka M. Sengsayadeth, Bridget Fitzgerald, Bharat Nandakumar, Bicky Thapa, Timothy Martin Schmidt, Rebecca Silbermann, Heidi Chen, Saurabh Chhabra, Natalie Callander, Shaji K Kumar, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10033–10035.

https://doi.org/10.1182/blood-2022-169589

Published: 2022

NARROW

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

MRD accelerating myeloma drug development

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Survival of Patients with Extranodal NK-Cell Lymphoma in the United States

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens

Evaluating Concordance between International Myeloma Working Group (IMWG) and Simplified Frailty Index (SFI) Among Older Adults with Multiple Myeloma (MM)

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only